ArticleAmerican journal of hematology2024

Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.

Stefan O Ciurea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.